Top

Published in:

01-03-2017 | Breast Oncology

Outcomes of Sentinel Lymph Node-Positive Breast Cancer Patients Treated with Mastectomy Without Axillary Therapy

Authors: Elizabeth FitzSullivan, MD, Roland L. Bassett, MS, Henry M. Kuerer, MD, PhD, Elizabeth A. Mittendorf, MD, PhD, Min Yi, MD, PhD, Kelly K. Hunt, MD, Gildy V. Babiera, MD, Abigail S. Caudle, MD, Dalliah M. Black, MD, Isabelle Bedrosian, MD, Chantal Reyna, MD, Mediget Teshome, MD, Funda Meric-Bernstam, MD, Rosa Hwang, MD

Published in: Annals of Surgical Oncology | Issue 3/2017

Abstract

Purpose

Early-stage breast cancer patients with minimal axillary disease identified by sentinel lymph node dissection (SLND) have low regional recurrence rates when treated with breast-conserving surgery and radiation therapy (XRT) and many avoid a completion axillary lymph node dissection (CLND). As the incidence of total mastectomy (TM) has increased, it has become important to characterize which TM patients with a positive SLN may not benefit from further axillary treatment.

Methods

An institutional database was utilized to identify patients treated with a TM for invasive breast cancer and who had a positive SLN from 1994 to 2010. Clinicopathologic factors were analyzed. Regional recurrence rate, recurrence-free survival (RFS), and overall survival (OS) were determined.

Results

A total of 525 patients with invasive breast cancer and a positive SLN were treated with TM, including 58 patients who did not have CLND or XRT and 12 patients who did not have CLND but did receive XRT. Median follow-up was 66 months. The incidence of regional recurrence was not significantly different for patients who received no further axillary treatment compared to those who underwent CLND without XRT or those treated with XRT without CLND (10 years rate: 3.8 vs. 1.6 and 0 % respectively). RFS and OS were not significantly different among patients who received no further axillary treatment compared to those who underwent CLND, XRT, or both.

Conclusions

In select patients with early-stage breast cancer treated with mastectomy with a positive SLN, CLND may be avoided without adversely affecting recurrence or survival.

Available only for authorised users

Peintinger F, Reitsamer R, Stranzl H, Ralph G. Comparison of quality of life and arm complaints after axillary lymph node dissection vs sentinel lymph node biopsy in breast cancer patients. Br J Cancer. 2003;89(4):648-52.CrossRefPubMedPubMedCentral

Blanchard DK, Donohue JH, Reynolds C, Grant CS. Relapse and morbidity in patients undergoing sentinel lymph node biopsy alone or with axillary dissection for breast cancer. Arch Surg. 2003;138(5):482-7; discussion 487-8.CrossRefPubMed

Giuliano AE, McCall L, Beitsch P, et al. Locoregional recurrence after sentinel lymph node dissection with or without axillary dissection in patients with sentinel lymph node metastases: the American College of Surgeons Oncology Group Z0011 randomized trial. Ann Surg. 2010;252(3):426-32; discussion 432-3.PubMed

Baruch AC, Wang H, Staerkel GA, Evans DB, Hwang RF, Krishnamurthy S. Immunocytochemical study of the expression of mesothelin in fine-needle aspiration biopsy specimens of pancreatic adenocarcinoma. Diagn Cytopathol. 2007;35(3):143-7.CrossRefPubMed

Cyr A, Gao F, Gillanders WE, Aft RL, Eberlein TJ, Margenthaler JA. Disease recurrence in sentinel node-positive breast cancer patients forgoing axillary lymph node dissection. Ann Surg Oncol. 2012;19(10):3185-91.CrossRefPubMedPubMedCentral

Bilimoria KY, Bentrem DJ, Hansen NM, et al. Comparison of sentinel lymph node biopsy alone and completion axillary lymph node dissection for node-positive breast cancer. J Clin Oncol. 2009;27(18):2946-53.CrossRefPubMed

Naik AM, Fey J, Gemignani M, et al. The risk of axillary relapse after sentinel lymph node biopsy for breast cancer is comparable with that of axillary lymph node dissection: a follow-up study of 4008 procedures. Ann Surg. 2004;240(3):462-8; discussion 468-71.CrossRefPubMedPubMedCentral

Jagsi R, Chadha M, Moni J, et al. Radiation field design in the ACOSOG Z0011 (Alliance) Trial. J Clin Oncol. 2014;32(32):3600-6.CrossRefPubMedPubMedCentral

Edge SB, Compton CC. The American Joint Committee on Cancer: the 7th edition of the AJCC cancer staging manual and the future of TNM. Ann Surg Oncol. 2010;17(6):1471-4.CrossRefPubMed

10.

Mittendorf EA, Hunt KK, Boughey JC, et al. Incorporation of sentinel lymph node metastasis size into a nomogram predicting nonsentinel lymph node involvement in breast cancer patients with a positive sentinel lymph node. Ann Surg. 2012;255(1):109-15.CrossRefPubMedPubMedCentral

11.

Galimberti V, Cole BF, Zurrida S, et al. Axillary dissection versus no axillary dissection in patients with sentinel-node micrometastases (IBCSG 23-01): a phase 3 randomised controlled trial. Lancet Oncol. 2013;14(4):297-305.CrossRefPubMedPubMedCentral

12.

Milgrom S, Cody H, Tan L, et al. Characteristics and outcomes of sentinel node-positive breast cancer patients after total mastectomy without axillary-specific treatment. Ann Surg Oncol. 2012;19(12):3762-70.CrossRefPubMed

13.

Snow R, Reyna C, Johns C, et al. Outcomes with and without axillary node dissection for node-positive lumpectomy and mastectomy patients. Am J Surg. 2015;210(4):685–93.CrossRefPubMed

14.

Yao K, Liederbach E, Pesce C, Wang CH, Winchester DJ. Impact of the American College of Surgeons Oncology Group Z0011 Randomized Trial on the number of axillary nodes removed for patients with early-stage breast cancer. J Am Coll Surg. 2015;221(1):71-81.CrossRefPubMed

15.

Boughey JC, Suman VJ, Mittendorf EA, et al. Sentinel lymph node surgery after neoadjuvant chemotherapy in patients with node-positive breast cancer: the ACOSOG Z1071 (Alliance) clinical trial. JAMA. 2013;310(14):1455-61.CrossRefPubMedPubMedCentral

16.

Garg AK, Buchholz TA. Influence of neoadjuvant chemotherapy on radiotherapy for breast cancer. Ann Surg Oncol. 2015;22(5):1434-40.CrossRefPubMed

Title: Outcomes of Sentinel Lymph Node-Positive Breast Cancer Patients Treated with Mastectomy Without Axillary Therapy
Authors: Elizabeth FitzSullivan, MD
Roland L. Bassett, MS
Henry M. Kuerer, MD, PhD
Elizabeth A. Mittendorf, MD, PhD
Min Yi, MD, PhD
Kelly K. Hunt, MD
Gildy V. Babiera, MD
Abigail S. Caudle, MD
Dalliah M. Black, MD
Isabelle Bedrosian, MD
Chantal Reyna, MD
Mediget Teshome, MD
Funda Meric-Bernstam, MD
Rosa Hwang, MD
Publication date: 01-03-2017
Publisher: Springer International Publishing
Published in: Annals of Surgical Oncology / Issue 3/2017
Print ISSN: 1068-9265
Electronic ISSN: 1534-4681
DOI: https://doi.org/10.1245/s10434-016-5605-5

Keynote webinar | Spotlight on sleep in brain health

Springer Medicine

Outcomes of Sentinel Lymph Node-Positive Breast Cancer Patients Treated with Mastectomy Without Axillary Therapy

Abstract

Purpose

Methods

Results

Conclusions

Keynote webinar | Spotlight on sleep in brain health

Springer Medicine

Abstract

Purpose

Methods

Results

Conclusions

Please log in to get access to this content

Other articles of this Issue 3/2017

Ultrasound-Guided Core-Needle Versus Vacuum-Assisted Breast Biopsy: A Cost Analysis Based on the American Society of Breast Surgeons’ Mastery of Breast Surgery Registry

Preoperative Neutrophil-Lymphocyte and Lymphocyte-Monocyte Ratios Reflect Immune Cell Population Rearrangement in Resectable Pancreatic Cancer

Long-Term Outcomes of 98 Surgically Resected Metastatic Tumors in the Pancreas

Extending ACOSOG Z0011 to Encompass Mastectomy: What Happens Without RT?

The Impact of Primary Care Providers on Patient Screening Mammography and Initial Presentation in an Underserved Clinical Setting

Is Routine Axillary Imaging Necessary in Clinically Node-Negative Patients Undergoing Neoadjuvant Chemotherapy?